Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now directly owns 7,177,116 shares in the company, valued at $68,254,373.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 11th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.45, for a total value of $96,727.15.
• On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.17, for a total value of $104,968.99.
• On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.95, for a total value of $91,003.65.
• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.

Recursion Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ:RXRX opened at $7.50 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.97 and a 1-year high of $16.75. The firm has a market capitalization of $1.78 billion, a PE ratio of -4.69 and a beta of 0.86. The business’s 50 day moving average is $8.84 and its 200-day moving average is $9.92.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the firm earned ($0.34) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 14.0% compared to the same quarter last year. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current year.

Wall Street Analyst Weigh In

RXRX has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday. KeyCorp raised their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. National Bank of Canada FI lifted its position in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after buying an additional 1,500 shares during the period. Wedmont Private Capital lifted its position in shares of Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after buying an additional 2,000 shares during the period. Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $26,000. Arizona State Retirement System lifted its position in shares of Recursion Pharmaceuticals by 8.5% during the 4th quarter. Arizona State Retirement System now owns 39,926 shares of the company’s stock worth $394,000 after buying an additional 3,125 shares during the period. Finally, Exchange Traded Concepts LLC lifted its position in shares of Recursion Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 16,359 shares of the company’s stock worth $161,000 after buying an additional 4,148 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.